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LETTER TO THE EDITOR
COPD: A controversial disease?
COPD  is  today  the  most  common  chronic  respiratory  disease
still  persists  the  concept  of  COPD  as  a  steroid-resistant
disease.12 Conﬂicting  with  this,  clinical  evidence  shows  an
effect  of  inhaled  corticosteroids  (ICS)  on  the  rate  of  COPD
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pand  a  growing  cause  of  worldwide  morbidity  and  mortality,
with  many  cardiovascular,  musculoskeletal,  metabolic  and
mental  sequelae,  some  usually  referred  to  as  comorbidities.
According  to  some  authors,  chronic  obstructive  pulmonary
disease  is  not  a  disease  in  the  true  sense  of  the  word,  but
a  very  popular  acronym.2 The  deﬁning  characteristics  of  a
disease  are  clinical  symptoms  and  signs,  structural  abnor-
malities,  function  disorders,  and  causation  or  etiology,3 but
COPD  is  a  heterogeneous  collection  of  different  pathophysi-
ological  processes  that  result  in  the  development  of  chronic
and  usually  progressive  airﬂow  limitation,4 as  deﬁned  by
GOLD.5 Poor  lung  development,  excess  lung  damage,  airway
remodeling  and  deﬁcient  lung  repair  are  different  processes
affecting  the  development  and  progression  of  COPD.  The
Fletcher--Peto  curve  remains  a  landmark  reference  for  the
natural  history  of  COPD,  but  because  of  the  heterogeneous
nature  of  the  disease,  several  natural  histories  are  possible,
and  there  may  be  patients  progressing  on  different  natural
history  trajectories,  from  slowly  progressive  to  rapidly  pro-
gressive  natural  histories.6 Now  we  recognize  that  the  term
COPD  brings  together  a  number  of  entities  with  different
clinical  and  pathophysiological  features,  hence  the  empha-
sis  given  to  the  great  diversity  of  phenotypes  of  COPD.7 This
emphasis  in  COPD  phenotypes  was  born  both  from  the  cur-
rent  trend  of  doing  a  patient-centered  medicine  and  from
the  need  to  understand  the  disease  in  its  heterogeneity.
COPD  is  characterized  by  persistent  airway  limitation
that  is  not  fully  reversible  and  is  usually  progressive.8
Obstruction  is  deﬁned  by  the  GOLD  as  a  post-bronchodilator
FEV1/FVC  <  0.7,  but  this  criterion  of  obstruction  has  been
increasingly  questioned,  and  because  there  is  currently  no
consensus  about  the  best  criterion  to  be  used  in  COPD,9
this  remains  a  matter  of  continuous  debate  in  literature.10
Furthermore,  even  though  obstruction  is  a  landmark  of  the
disease,  some  authors  wonder  if  obstruction  does  always
need  to  be  present  in  early  stages,  or  if  emphysema,  in
the  absence  of  obstruction,  represents  COPD.4 However,  in
any  stage  of  the  disease,  and  despite  obstruction  not  being
fully  reversible,  bronchodilators  remain  the  cornerstone  of
the  treatment,  since  they  usually  cause  a  signiﬁcant  clinicalPlease  cite  this  article  in  press  as:  Araújo  A.  COPD:  
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improvement,  even  without  signiﬁcantly  modifying  FEV1.11
Inﬂammation  plays  a  central  role  in  the  pathogenesis
of  COPD,  and  keeps  on  after  smoking  cessation,  but  there
d
p
o
http://dx.doi.org/10.1016/j.rppnen.2016.03.015
2173-5115/© 2016 Sociedade Portuguesa de Pneumologia. Published by 
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)xacerbations  and  in  quality  of  life,13 and  consensus  was
eached  regarding  the  indication  of  ICS  in  ACOS  and  fre-
uent  exacerbating  phenotypes.14 ICS  have  some  adverse
ffects,  the  increased  incidence  of  pneumonia  being  the
est-documented  treatment  risk,15 but,  paradoxically,  the
isk  of  dying  is  not  higher  in  ICS  treated  patients.  Neverthe-
ess,  ICS  have  been  widely  used,  with  more  than  70%  of  COPD
atients  being  treated  with  ICS,16 and  observational  studies
ave  shown  the  persistence  of  an  excessive  use  of  ICS  in
ild  COPD.  This  extensive  use  is  discrepant  from  treatment
uidelines,  but  the  use  of  ICS  in  COPD  is  still  an  impor-
ant  matter  of  debate,  as  is  the  question  of  the  effects  of
iscontinuation  of  ICS.
In  the  general  population,  the  beneﬁts  of  physical  activ-
ty  are  well  documented.  Physical  inactivity  is  a  central
roblem  in  COPD  patients  in  all  severity  stages  of  the  dis-
ase,  it  plays  a  crucial  role  in  the  development  of  COPD
omorbidities  and  it  is  the  best  predictor  of  all-cause  mor-
ality  in  these  patients.17 Physical  activity  can  be,  along  with
moking  cessation,  the  best  cost-beneﬁt  measure  to  pre-
ent  disease  progression,  comorbidities  and  mortality.  As
ecreased  physical  activity  is  already  present  early  in  the
evelopment  of  the  disease,  the  implementation  of  regular
hysical  activity  should  be  an  important  secondary  preven-
ion  strategy.  However,  GOLD  and  many  other  guidelines  do
ot  include  any  recommendations  regarding  physical  activ-
ty  in  COPD,  which  take  into  account  the  physical  exercise
equirements  in  relations  to  duration,  frequency  and  inten-
ity.  The  recently  published  ATS/ERS  statement,8 regarding
he  types  of  research  which  will  have  the  greatest  impact
n  patient-centered  outcomes  in  COPD,  does  not  refer  to
ny  research  recommendation  regarding  physical  exercise,
xcept  for  pulmonary  rehabilitation.
Despite  all  these  controversies,  COPD  is  a  disease  deﬁned
y  a  function  disorder.  Although  heterogeneous  and  associ-
ted  with  a  chronic  inﬂammatory  response  in  the  airways
nd  lungs,  COPD  is  an  obstructive  disease;  the  airﬂow
imitation  is  chronic,  not  fully  reversible  and  usually  progres-
ive.  In  medical  discourse,  a  disease  is  a  sum  of  abnormal
henomena  that  place  a  living  organism  in  a  biologicalA  controversial  disease?  Rev  Port  Pneumol.  2016.
isadvantage,  and  its  deﬁning  characteristics  may  only  be
athophysiological.18 The  name  of  a  disease  is  a  conclusion
f  a  diagnostic  process,  the  purpose  of  which  is  more  to
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implify  and  clarify  the  medical  discourse  than  to  decide
 treatment  for  a  given  patient.  In  pulmonary  medicine,  it
s  important  to  distinguish  between  the  connotation  of  the
ord  obstruction  as  a  function  disorder,  or  a  disease  like
OPD.
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